Kerwin F Shannon
Overview
Explore the profile of Kerwin F Shannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Newell F, Pires da Silva I, Johansson P, Menzies A, Wilmott J, Addala V, et al.
Cancer Cell
. 2025 Feb;
43(3):563.
PMID: 39919735
No abstract available.
2.
Novis E, Sulaiman A, Stretch J, Chung D, London K, Wong T, et al.
Eur J Surg Oncol
. 2024 Dec;
51(2):109538.
PMID: 39662108
Background: Although most melanomas drain to the more common major lymph node basins (axilla, groin, neck), rarely they drain to deep SLN locations such as intra-abdominal and intra-thoracic (including intercostal...
3.
Lin V, Zhang M, Gupta R, Elliott M, Clark J, Wykes J, et al.
Head Neck
. 2024 Nov;
47(4):1109-1116.
PMID: 39584376
Background: Cutaneous squamous cell carcinomas (cSCC) metastasizing to the parotid gland can cause facial nerve (FN) dysfunction secondary to direct invasion, perineural spread, or surgical ablation. This study aims to...
4.
Li A, Xu J, Blah T, Lo S, Saw R, Varey A, et al.
J Am Acad Dermatol
. 2024 Sep;
92(1):58-67.
PMID: 39243946
Background: Melanoma is increasingly recognized as a heterogeneous disease, with conflicting evidence regarding whether cutaneous head and neck melanoma (CHNM) represents a distinct entity. Objective: Comparison of clinicopathological features and...
5.
Quek C, Pratapa A, Bai X, Al-Eryani G, Pires da Silva I, Mayer A, et al.
Cell Rep
. 2024 Jun;
43(7):114392.
PMID: 38944836
Heterogeneous resistance to immunotherapy remains a major challenge in cancer treatment, often leading to disease progression and death. Using CITE-seq and matched 40-plex PhenoCycler tissue imaging, we performed longitudinal multimodal...
6.
Long G, Carlino M, Au-Yeung G, Spillane A, Shannon K, Gyorki D, et al.
Nat Med
. 2024 Jun;
30(9):2540-2548.
PMID: 38907159
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative,...
7.
Blank C, Lucas M, Scolyer R, van de Wiel B, Menzies A, Lopez-Yurda M, et al.
N Engl J Med
. 2024 Jun;
391(18):1696-1708.
PMID: 38828984
Background: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. Methods: In this phase 3 trial, we randomly assigned...
8.
Winder A, Boyer Z, Chng S, Stretch J, Saw R, Shannon K, et al.
Ann Surg Oncol
. 2024 May;
31(8):5331-5339.
PMID: 38802717
Background: Predicting which patients with American Joint Committee on Cancer (AJCC) T1-T2 melanomas will have a positive sentinel lymph node (SLN) is challenging. Melanoma Institute Australia (MIA) developed an internationally...
9.
Zijlker L, Chen H, Spillane A, Gonzalez M, Pennington T, Menzies A, et al.
Ann Surg Oncol
. 2024 May;
31(8):5324-5330.
PMID: 38762644
Background: Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with...
10.
Varey A, Li I, El Sharouni M, Simon J, Dedeilia A, Chng S, et al.
J Clin Oncol
. 2024 Feb;
42(10):1169-1180.
PMID: 38315961
Purpose: Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However,...